# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Melanoma, cutaneous malignant 6

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 14 results.
Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery
Status: Recruiting
Last Changed: Jun 19, 2019
First Received: Dec 27, 2017
Disease(s): Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Intervention(s): Laboratory Biomarker Analysis, Pembrolizumab, Propranolol Hydrochloride
Locations: Roswell Park Cancer Institute, Buffalo, New York, United States
Penn State Milton S. Hershy Medical Center Cancer Institute, Hershey, Pennsylvania, United States
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
Status: Recruiting
Last Changed: Jul 19, 2019
First Received: Dec 04, 2012
Disease(s): Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Intervention(s): Aldesleukin, CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, NGFR-transduced Autologous T Lymphocytes, Quality-of-Life Assessment
Locations: M D Anderson Cancer Center, Houston, Texas, United States
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Status: Recruiting
Last Changed: Jan 04, 2019
First Received: Sep 08, 2017
Disease(s): Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Intervention(s): Imiquimod, Laboratory Biomarker Analysis, Pembrolizumab
Locations: Mayo Clinic in Florida, Jacksonville, Florida, United States
Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery
Status: Recruiting
Last Changed: May 03, 2019
First Received: Oct 30, 2017
Disease(s): Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Intervention(s): Cryosurgery, Pembrolizumab, Pheresis, Therapeutic Autologous Dendritic Cells
Locations: Mayo Clinic, Rochester, Minnesota, United States
Nivolumab With or Without Ipilimumab or Relatlimab Before Surgery in Treating Patients With Stage IIIB-IV Melanoma That Can Be Removed by Surgery
Status: Recruiting
Last Changed: May 30, 2019
First Received: Aug 10, 2015
Disease(s): Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage III Acral Lentiginous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Acral Lentiginous Melanoma AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
Intervention(s): Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Relatlimab, Therapeutic Conventional Surgery
Locations: M D Anderson Cancer Center, Houston, Texas, United States
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma
Status: Recruiting
Last Changed: Feb 27, 2019
First Received: Feb 07, 2018
Disease(s): Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Intervention(s): Anti-SEMA4D Monoclonal Antibody VX15/2503, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma
Status: Recruiting
Last Changed: Jul 15, 2019
First Received: Oct 07, 2013
Disease(s): Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Intervention(s): Aldesleukin, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, NGFR-transduced Autologous T Lymphocytes, TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
Locations: M D Anderson Cancer Center, Houston, Texas, United States
Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
Status: Recruiting
Last Changed: Jun 17, 2019
First Received: Nov 04, 2015
Disease(s): AIDS-Related Non-Hodgkin Lymphoma, Classic Hodgkin Lymphoma, HIV Infection, Locally Advanced Malignant Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Cutaneous Melanoma, Recurrent Hepatocellular Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Kaposi Sarcoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Malignant Neoplasm, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Refractory Malignant Neoplasm, Refractory Malignant Solid Neoplasm, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7
Intervention(s): Laboratory Biomarker Analysis, Pembrolizumab
Locations: Zuckerberg San Francisco General Hospital, San Francisco, California, United States
UCSF Medical Center-Parnassus, San Francisco, California, United States
Yale University, New Haven, Connecticut, United States
Louisiana State University Health Science Center, New Orleans, Louisiana, United States
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
... and 6 other locations.
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Recruiting
Last Changed: Oct 15, 2019
First Received: Jan 27, 2017
Disease(s): Advanced Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma, Refractory Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Cutaneous Melanoma, Unresectable Melanoma
Intervention(s): Ipilimumab, Nivolumab
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
Alaska Women's Cancer Care, Anchorage, Alaska, United States
... and 615 other locations.
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
Status: Recruiting
Last Changed: Oct 18, 2019
First Received: Aug 25, 2014
Disease(s): Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Cutaneous Melanoma
Intervention(s): Dabrafenib, Dabrafenib Mesylate, Ipilimumab, Nivolumab, Quality-of-Life Assessment, Trametinib, Trametinib Dimethyl Sulfoxide
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
... and 784 other locations.